Article
Washington, DC — Nidek Inc. has received FDA marketing clearance for commercial release of its new MC-300 multicolor laser photocoagulator system. The company also announced that its new state-of-the-art YC-1800 ophthalmic YAG laser system is available for sale to the U.S. market.
April 18 - Washington, DC - Nidek Inc. has received FDA marketing clearance for commercial release of its new MC-300 multicolor laser photocoagulator system. The company also announced that its new state-of-the-art YC-1800 ophthalmic YAG laser system is available for sale to the U.S. market.
The MC-300 laser system has been commercially available in international markets and has received outstanding reviews and clinical results from retinal specialists in Asia and Europe.
The Nidek MC-300 is an advanced multi-color (red, yellow, and green) diode-pumped solid-state laser system. The new laser delivers three unique laser wavelengths (659, 561, and 532 nm) that are ideal for retinal applications, disease treatments, and management. The new retinal photocoagulator features advanced software technologies for accurate and precise energy delivery to the retina. The MC-300 laser can be mounted for slit-lamp delivery and requires a standard electric outlet, offering retinal surgeons with advanced delivery capabilities and versatility in either an operating room or in-office use.
The Nidek YC-1800 YAG laser system is an advanced ophthalmic laser platform that combines innovative laser delivery and output technologies, improved operability, fast operation, super adjustable Nd:YAG offset, and compact design with versatility for combination laser systems.
Study validates long-term efficacy of MicroPulse TLT for glaucoma management